166 related articles for article (PubMed ID: 32219500)
21. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
22. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
23. A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
Zhang L; Zhu J; Hou Y; Li C; Liu H
J Cancer Res Ther; 2021 Dec; 17(7):1702-1708. PubMed ID: 35381742
[TBL] [Abstract][Full Text] [Related]
24. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.
Barnea I; Ben-Yosef R; Karaush V; Benhar I; Vexler A
Head Neck; 2013 Aug; 35(8):1171-7. PubMed ID: 22965815
[TBL] [Abstract][Full Text] [Related]
25. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Ichiyama M; Tsumoto K; Asano R; Kumagai I; Imai K; Hinoda Y; Matsuno S; Kudo T
Cancer Immunol Immunother; 2001 Dec; 50(10):539-48. PubMed ID: 11776376
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using (99m)technetium-labeled anti-KL-6/MUC1 antibody.
Matsumura K; Niki I; Tian H; Takuma M; Hongo N; Matsumoto S; Mori H
Radiat Med; 2008 Apr; 26(3):133-9. PubMed ID: 18683568
[TBL] [Abstract][Full Text] [Related]
27. Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo.
Zhang L; Hou Y; Li C; Liu H; Wang Y
Arab J Gastroenterol; 2022 Nov; 23(4):263-269. PubMed ID: 35922259
[TBL] [Abstract][Full Text] [Related]
28. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
29. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma.
Rahman A; Matsuyama M; Ebihara A; Shibayama Y; Hasan AU; Nakagami H; Suzuki F; Sun J; Kobayashi T; Hayashi H; Nakano D; Kobara H; Masaki T; Nishiyama A
Mol Cancer Ther; 2020 Sep; 19(9):1844-1855. PubMed ID: 32669314
[TBL] [Abstract][Full Text] [Related]
31. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
Schettini J; Kidiyoor A; Besmer DM; Tinder TL; Roy LD; Lustgarten J; Gendler SJ; Mukherjee P
Cancer Immunol Immunother; 2012 Nov; 61(11):2055-65. PubMed ID: 22543528
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
34. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro.
Shimizu M; Imai M
Biol Pharm Bull; 2008 Dec; 31(12):2288-93. PubMed ID: 19043215
[TBL] [Abstract][Full Text] [Related]
35. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
36. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
37. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
38. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
40. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer.
Curry JM; Thompson KJ; Rao SG; Besmer DM; Murphy AM; Grdzelishvili VZ; Ahrens WA; McKillop IH; Sindram D; Iannitti DA; Martinie JB; Mukherjee P
J Surg Oncol; 2013 Jun; 107(7):713-22. PubMed ID: 23335066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
